HLS signs promotional deal with Pfizer
Pharmaceutical company HLS Therapeutics of Toronto has signed an agreement with Pfizer to promote its Vascepa cardiovascular medication in Canada. The product is intended to reduce the risk of major cardiac events such as cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, coronary revascularization or hospitalization for unstable angina in statin-treated patients.
Under terms of the agreement, Pfizer promotional workers will conduct a national awareness initiative aimed at primary care physicians. HLS’s own marketing staff will focus on specialist physicians.
“We believe Vascepa has the potential to improve the lives of the many Canadians suffering from, or at risk of, cardiovascular disease, and we look forward to collaborating with Pfizer to bring this innovative therapy to those in need,” said Gilbert Godin, CEO of HLS. “This partnership will enable us to educate and efficiently expand interactions with a general physician audience that is three to four times larger. Ultimately, we believe this collaboration will benefit patients and physicians while at the same time strengthening the economic potential for the product and expanding the benefit to society.”